Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.69 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29824252 | 1.00 | KCNA5 (1.00) | KCNA5KCNH2CYP19A1ALOX12MEN1 | |
| SCHEMBL23648962 | 0.95 | KCNA5 (0.90) | KCNA5KCNH2CYP19A1ALOX12MEN1 | |
| SCHEMBL29824438 | 0.95 | KCNA5 (0.90) | KCNA5KCNH2CYP19A1ALOX12MEN1 | |
| SCHEMBL23648947 | 0.93 | KCNA5 (0.86) | KCNA5KCNH2CYP19A1ALOX12MEN1 | |
| SCHEMBL29824486 | 0.93 | KCNA5 (0.86) | KCNA5KCNH2CYP19A1ALOX12MEN1 | |
| SCHEMBL2950890 | 0.87 | ALOX12 (0.84) | KCNA5KCNH2CYP19A1ALOX12 | |
| SCHEMBL2947799 | 0.86 | KCNA5 (0.76) | KCNA5KCNH2CYP19A1MEN1KMT2A | |
| SCHEMBL2945795 | 0.86 | ALOX12 (0.90) | KCNA5KCNH2CYP19A1ALOX12 | |
| SCHEMBL23648916 | 0.85 | KCNA5 (0.74) | KCNA5KCNH2MEN1KMT2AALDH1A1 | |
| SCHEMBL29824627 | 0.85 | KCNA5 (0.74) | KCNA5KCNH2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | PIMEDBIO, INC. (KR) | 2023-05-11 | — | — | US | claimed |
| EP-4065553-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | Daegu-Gyeongbuk Medical Innovation Foundation (KR) | 2022-10-05 | — | — | EP | claimed |
| CN-114981241-A | Novel compound, preparation method and application thereof | 大邱庆北尖端医疗产业振兴财团 | 2022-08-30 | — | — | CN | claimed |
| WO-2021145729-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2021-07-22 | — | — | WO | claimed |
| US-7754755-B2 | e.g. N-[2-(1H-Indol-3-yl)-ethyl]-2-methyl-5-fluoro-benzenesulfonamide; N-[3-(4-Butyl-phenoxy)-propyl]-4-pentyl-benzenesulfonamide; useful for treating inflammatory disorder, atherosclerosis, diabetes, vascular restenosis, hypertension, asthma, rheumatoid arthritis, osteoarthritis, cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-13 | — | — | US | claimed |
| US-12583818-B2 | Compound, preparation method thereof, and use thereof | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2026-03-24 | — | — | US | disclosed |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | PIMEDBIO, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | PIMEDBIO, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
| EP-4065553-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | Daegu-Gyeongbuk Medical Innovation Foundation (KR) | 2022-10-05 | — | — | EP | disclosed |
| CN-114981241-A | Novel compound, preparation method and application thereof | 大邱庆北尖端医疗产业振兴财团 | 2022-08-30 | — | — | CN | disclosed |
| WO-2021145729-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2021-07-22 | — | — | WO | disclosed |
| WO-2021145729-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2021-07-22 | — | — | WO | disclosed |
| US-7754755-B2 | e.g. N-[2-(1H-Indol-3-yl)-ethyl]-2-methyl-5-fluoro-benzenesulfonamide; N-[3-(4-Butyl-phenoxy)-propyl]-4-pentyl-benzenesulfonamide; useful for treating inflammatory disorder, atherosclerosis, diabetes, vascular restenosis, hypertension, asthma, rheumatoid arthritis, osteoarthritis, cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754755-B2 | e.g. N-[2-(1H-Indol-3-yl)-ethyl]-2-methyl-5-fluoro-benzenesulfonamide; N-[3-(4-Butyl-phenoxy)-propyl]-4-pentyl-benzenesulfonamide; useful for treating inflammatory disorder, atherosclerosis, diabetes, vascular restenosis, hypertension, asthma, rheumatoid arthritis, osteoarthritis, cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754755-B2 | e.g. N-[2-(1H-Indol-3-yl)-ethyl]-2-methyl-5-fluoro-benzenesulfonamide; N-[3-(4-Butyl-phenoxy)-propyl]-4-pentyl-benzenesulfonamide; useful for treating inflammatory disorder, atherosclerosis, diabetes, vascular restenosis, hypertension, asthma, rheumatoid arthritis, osteoarthritis, cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-13 | — | — | US | disclosed |
| US-20060063823-A1 | e.g. N-[2-(1H-Indol-3-yl)-ethyl]-2-methyl-5-fluoro-benzenesulfonamide; N-[3-(4-Butyl-phenoxy)-propyl]-4-pentyl-benzenesulfonamide; useful for treating inflammatory disorder, atherosclerosis, diabetes, vascular restenosis, hypertension, asthma, rheumatoid arthritis, osteoarthritis, cancer | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583818-B2 | Compound, preparation method thereof, and use thereof | TYRO3, TH, SRMS | KCNA5 3937/4885KCNH2 4556/4885CYP19A1 123/4885 |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | TYR, TYRO3, TH | KCNA5 4313/4885KCNH2 4707/4885CYP19A1 465/4885 |
| US-20060063823-A1 | e.g. N-[2-(1H-Indol-3-yl)-ethyl]-2-methyl-5-fluoro-benzenesulfonamide; N-[3-(4-Butyl-phenoxy)-propyl]-4-pentyl-benzenesulfonamide; useful for treating inflammatory disorder, atherosclerosis, diabetes, vascular restenosis, hypertension, asthma, rheumatoid arthritis, osteoarthritis, cancer | PTGIS, MMP15, IL15 | KCNA5 1389/4885KCNH2 2410/4885CYP19A1 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.